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Transforming growth factor 1 (TGF1) modulates cell proliferation, promotes mesenchymal cell differentiation with enhanced deposition of extracellular matrix and has immunosuppressive properties [1] . The specific action of TGF1 on a particular cell depends on differential expression of its receptors and allows for a precise response in differing cellular environments [2] .
A substantial body of evidence implicates altered activity of TGF1 in the pathogenesis of systemic sclerosis (SSc) [3, 4] . Persuasive support comes from the profound effects of TGF1 on fibroblasts inducing a fibrogenic phenotype and promoting differentiation of myofibroblasts [5] . Other evidence is provided by studies reporting increased expression of TGF ligand in many experimental models of fibrosis and indirectly from a number of studies that demonstrate perturbed TGF signalling in SSc fibroblasts [6, 7] . In addition, it is a potent immunosuppressive cytokine and an important product of regulatory lymphocyte subpopulations [8] . Consistent with this broad range of important biological properties, TGF1 bioactivity is tightly regulated [9] . This regulation includes a non-covalent association with latency associated peptide (LAP) to form biologically inactive latent TGF complex. Dissociation from LAP is necessary for biological activity and mechanisms of activation may differ according to physiological or pathological context [10] . Serum and plasma levels of TGF isoforms have been measured in several diseases [2] but the results have been conflicting. One limitation has been the discrimination between latent and active forms; another potential confounder is that serum levels may be difficult to interpret due to release of TGF from platelets ex vivo. Consequently, the significance of circulating levels of this profibrotic factor remains unclear [11] . Levels of TGF1 in SSc have previously been measured using low-sensitivity assays, with discordant results [12] [13] [14] [15] [16] [17] [18] . Interpretation is confounded as some assays detect TGF1 in its biologically inactive latent form and are not specific for active 25 kDa protein. Clinical heterogeneity and a lack of the standardized assessment of clinical variables has limited interpretation of these earlier studies [19] .
We have examined serum and plasma levels of TGF1 in well-characterized patients with SSc and investigated correlation(s) with clinical variables as well as with disease activity and severity indices [20, 21] .
Methods

Study subjects
Patients fulfilled the American College of Rheumatology (formerly the American Rheumatism Association) preliminary criteria for the classification of SSc [22] . Twenty-seven patients (20 female, 7 male) had diffuse cutaneous systemic sclerosis (dcSSc) and 20 patients (16 female, 4 male) had limited cutaneous systemic sclerosis (lcSSc) [23] . Disease duration was defined as the time from onset of the first non-Raynaud's manifestation of SSc. Clinical assessment of skin sclerosis was performed concurrently with blood sampling: skin score was measured by the modified Rodnan skin scoring technique [24] . The presence of antinuclear antibodies, anticentromere antibodies, antidouble-stranded DNA (dsDNA) antibodies, antiextractable nuclear antigen (ENA) antibodies including anti-Scl-70, anti-PM-Scl, anti-nRNP, anti-Jo-1, anti-Ro and anti-La, anti-Sm and anti-polymerase I and III antibodies as well as rheumatoid factor was determined by validated assays. Patients were screened for major visceral complications of SSc according to current standard practice including pulmonary function tests, ECG, Doppler echocardiography and calculated creatinine clearance. When these basic tests were abnormal, further investigation by high-resolution CT scan (HRCT) or right heart catheterization was performed. Pulmonary hypertension (PHT) was defined by mean pulmonary artery pressure (PAP) above 25 mmHg at rest or 30 mmHg on exercise. Lung fibrosis was determined by HRCT, renal involvement by creatinine clearance of less than 60 ml/min or history of scleroderma renal crisis, and gastrointestinal tract involvement was determined by typical history or abnormal investigations prompted by symptoms. Skeletal muscle involvement was determined by creatine kinase (CPK) greater than four times the upper limit of normal. Disease activity and severity were determined according to the guidelines formulated recently [21] . Briefly, in the assessment of disease activity, the following parameters were evaluated and scored: modified Rodnan skin score, presence of scleredema, any recent worsening of the cutaneous/vascular/ cardiopulmonary involvement, active digital ulcers, presence of arthritis, diffusing lung capacity for carbon monoxide (DLCO) 580%, erythrocyte sedimentation rate (ESR) >30 and low levels of serum complement. Scoring was different for each of those parameters with the total score ranging from 0 to 10. The disease was considered active if the score was !3. The assessment of disease severity was based on the evaluation of nine organs/ systems: general, peripheral vascular, skin, joints and tendons, muscles, gastrointestinal tract, lung, heart and kidneys. The severity of the involvement of each organ was evaluated following guidelines and scored from 0-4, where 0 was normal or no involvement, 1 mild, 2 moderate, 3 severe and 4 end-stage. The single scores were summarized and the final value denoted disease severity.
Control samples were obtained from 22 healthy volunteers (Table 1 ).
Blood sampling
Blood samples were taken from each subject in the morning. Serum and plasma samples were obtained by centrifugation of whole blood at 3000 g for 10 min and aliquots were stored at À20 C until assayed. Levels of TGF1 were measured using a high-sensitivity sandwich immunoassay specific for the active ligand (Promega, WI, USA), according to the manufacturer's protocol. Each sample was assayed in triplicate.
In brief, the 96-well microtitre plates were coated with 100 l per well of anti-TGF1 monoclonal antibody diluted in carbonate coating buffer (concentration 1 l/ml), which binds soluble TGF1. After incubation overnight at 4 C, TGF1 standard (Promega) or test samples (dilution 1:50) were added to the wells and reacted for 90 min at room temperature. The plates were then incubated with 1 l/ml of biotinylated anti-TGF1 polyclonal antibody (Promega) for 2 h at room temperature and subsequently with 10 l/ml of horseradish peroxidase (HRP) conjugated antibody for 2 h. The colour reaction was induced by the addition of substrate solution (tetramethylbenzidine/hydrogen peroxide) and was stopped with 100 l 1 N HCl. An automated microplate reader was used to measure the optical density (OD) at a wavelength of 450 nm. Between each of these steps the plates were washed five times with TBST wash buffer. Baseline and acidtreated samples for each subject were analysed. For the measurements of naturally occurring active TGF1, serum or plasma samples were diluted 1:50 in the sample buffer provided. For total TGF1 levels, an aliquot of the sample was diluted 1:5 in Dulbecco's phosphate buffered saline and treated with 1 N HCl for 15 min (obtaining a sample pH of approximately 2.6); subsequently samples were neutralized with 1 N NaOH to a pH of approximately 7.6. Acid-treated standard TGF1 supplied at a concentration of 1 mg/ml was used as a calibration standard at concentrations ranging from 15.6 to 1000 ng/l.
Statistical analysis
Medians and interquartile ranges were used to express summary statistics. The Kruskal-Wallis test was used to compare outcome between several groups, and the Mann-Whitney test for differences between two groups. Active TGF1 data are skewed and a logarithmic transformation was carried out in order to normalize them. Linear association between variables was explored using the method of least squares. The square of the correlation coefficient, R, is reported and confidence intervals on the slope of the lines presented. Correlations between active TGF1 and disease duration and skin score were sought using log 10 transformed active TGF1 values. Group differences between the detectable and undetectable concentrations of TGF1 were tested using 2 test. Differences were considered significant if P 0.05.
Results
Demographic and clinical features of study cohort
These are summarized in Tables 1 and 2 . The healthy control group was younger than both patient groups (P ¼ 0.001), but lcSSc and dcSSc groups were age-matched. Gender differences were ignored in all analyses as there was a 36:11 F:M ratio in the study cohort, reflecting the expected female preponderance for SSc. Five of 27 patients with dcSSc and seven of 20 patients with lcSSc had isolated pulmonary hypertension. Thirteen of 27 dcSSc patients and eight of 20 lcSSc patients had lung fibrosis. There was a nonlinear relationship between skin score and time from diagnosis for the dcSSc group; (R 2 ¼ 0.4995, P50.00006) reflecting the fact that in the first few years of the disease skin scores are at their highest.
Circulating TGF1 levels
The median, range and interquartile range of the serum TGF1 concentrations (g/l) are shown in Table 3 . Single patient measurements are shown in Fig. 1a and b. Total levels of TGF1 were detected in all HC and SSc samples. We did not detect circulating levels of active TGF1 in 7/22 of HC, 7/20 of lcSSc and 18/27 of dcSSc ( 2 ¼ 7.39, P50.025). The samples with undetectable levels of TGF1 were analysed for the second time at lower dilution (1:10) and the levels remained undetectable in all samples. Whilst total TGF1 levels were marginally higher in dcSSc than lcSSc or HC, these differences did not reach significance (P50.08 HC vs dcSSc). The values for active TGF1 were skewed and therefore a logarithmic transformation (log 10 ) was carried out. Zero values, evenly spread across the groups (n ¼ 5 in HC, n ¼ 6 in lcSSc and n ¼ 4 in dcSSc) were excluded from the final analysis and from the graphical representation of the data (Fig. 1a) . The Kruskal-Wallis test was significant (P50.01) and dcSSc was significantly different from HC (P50.01) and lcSSc (P50.02). For comparison, plasma TGF1 levels reflected those of contemporary serum samples but were, on average, 30% lower than in serum in all groups, which is in keeping with published reports [16] .
In dcSSc (but not in lcSSc), there was a negative correlation between skin score and log 10 circulating serum active TGF1 (R 2 ¼ 0.194, P50.04) and also a positive correlation between log 10 circulating serum active TGF1 levels and disease duration (R 2 ¼ 0.198, P50.04) (Fig. 2) . There was a positive correlation between total serum TGF1 and disease duration in lcSSc (R 2 ¼ 0.229, P50.05) but not in dcSSc (Fig. 3) . Confidence intervals were calculated for the slopes of those plots in Figs 2  and 3 , where a significant relationship was found. For active TGF1 in dcSSc vs skin score, the slope was À0.038 [confidence interval (CI) À0.072 to À0.004]. The slopes for active TGF1 in dcSSc vs disease duration was 0.093/yr (CI 0.011 to 0.174) and total TGF1 in lcSSc vs disease duration was 3.10 mg/ml/yr (CI 0.40-5.80). No correlation was found between total TGF1 and skin score (Fig. 3) . Also, no correlation was found between the circulating levels of either active TGF1 or total TGF1 and disease activity or severity scores in both dcSSc and lcSSc. No difference in concentration of either active TGF1 or total TGF1 was observed when patients were categorized as those with PHT or those without PHT as well as those with or without lung fibrosis. Finally, there was no correlation between active or total TGF1 and age in any of the groups (HC, lcSSc and dcSSc).
Discussion
In this study we have used a high-sensitivity enzyme-linked immunosorbent assay (ELISA) to measure circulating levels of TGF1 in patients with SSc and in healthy controls (HC). We have determined and compared active and total TGF1 levels; the latter obtained after serum acidification, and compared then Scleroderma activity is scored between 0-10: active disease is denoted by a score ! 3. The severity of organ involvement is scored between 0 and 4, with 0 denoting no involvement. The median and range shown is for all patients in a group. Scleroderma severity score ranges from 0 to 36. with clinical features. We found low or undetectable levels of active TGF1 in early dcSSc, which correlated inversely with skin score. In contrast, levels of active TGF1 in lcSSc did not differ from HC; there were no significant differences in total TGF1 between the groups. The presence of substantial levels of active TGF1 in HC in this study and in other reports [15] [16] [17] suggests that it is not detrimental and raises the possibility that TGF1 may be important, for example, as a modulator of immune cell function. Low serum levels of active TGF1 in early dcSSc and the inverse correlation with modified Rodnan skin score have clinical relevance in the context of the evaluation of the extent of skin sclerosis. Skin score constitutes a key clinical parameter for assessing disease severity and predicting prognosis: severe skin involvement has been associated with poor prognosis, decreased survival and a greater risk of developing scleroderma renal crisis, pulmonary fibrosis and myocardial disease [25] . The biological significance of our results should be interpreted in the context of the physiology of TGF1. Important potential sources of circulating TGF1 are activated macrophages, T lymphocytes, platelets and endothelial cells. Active TGF1 is generated from latent TGF1 complex at sites of injury by a combination of proteolysis and low pH. In human serum TGF1 is bound covalently by alpha-2 macroglobulin ( 2 M) in an inactive form; the interaction of TGF1 with 2 M accounts for the latency of serum TGF [26] . It has been suggested that the majority of serum TGF in the form of a covalent complex with 2 M may represent TGF targeted for clearance via the 2 M receptor whereas the non-covalent complex might reflect a protected serum pool of potentially active TGF to be carried and released at target sites [26] . Active TGF1 is rapidly cleared by mechanisms which include binding to 2 M, decorin and soluble TGF receptors, followed by its clearance via the liver [2, 27, 28] . In the context of systemic sclerosis, in vitro protein and mRNA expression studies have revealed that SSc fibroblasts do not secrete more TGF than normal cells [29] ; it has been shown that overexpression of either type I or type II TGF receptors significantly increases alpha2(I) collagen promoter activity in transient transfection assays in dermal fibroblasts [30] . Addition of anti-TGF antibody abolished the stimulatory effect of receptor overexpression on collagen promoter activity. Comparison of TGF receptor type I and type II mRNA expression levels in SSc and normal fibroblasts have shown elevated (2-fold) expression of both receptor types in SSc cells, which correlated with increased binding of TGF and with elevated alpha2(I) collagen mRNA levels [30, 31] .
A plausible explanation for our findings is that increased binding sites or altered turnover of active TGF1 may reduce the level of active cytokine in dcSSc. There are several reports suggesting increased expression of TGF receptors in SSc [30] [31] [32] . In addition, a number of potential TGF-interacting proteins such as fibrillin or decorin are present at elevated levels in SSc, and extracellular matrix binding sites are likely to be increased [33] [34] [35] . Whether this is a primary pathogenetic process or a bystander phenomenon is unclear. However, it is interesting to speculate that in the active phase of early dcSSc and in cases with extensive skin involvement, an increase in cell surface and extracellular matrix TGF binding sites may sequester active TGF1 as it becomes released from the latent complex. This may augment the matrix stimulating activity of TGF1 and explain why relatively low levels are detectable in SSc since bound TGF1 may not be readily accessible for immunolocalization; low circulating level of TGF1 may reduce endogenous immunosuppressive activity and contribute to the increased immunological activity in early dcSSc that is a hallmark of this disease subset.
Previous studies of circulating serum or plasma TGF levels in SSc [12] [13] [14] [15] [16] [17] [18] have generated discordant results. For example, Falanga and Julien [12] did not detect any difference in the levels of circulating plasma TGF between SSc patients and healthy controls; they reported, however, increased TGF binding to SSc fibroblasts in culture and immunocytochemically detectable TGF in inflammatory infiltrates from SSc skin biopsy samples, and it has recently been reported that mononuclear cells in dcSSc produce increased amounts of TGF1 in vitro [36] . Keystone et al. [13] found elevated serum TGF in patients with dcSSc and lcSSc; correlations with clinical variables have not been analysed in this abstract. Higley et al. [14] found no significant difference in plasma concentrations of active TGF1 between SSc patients and HC, using a low sensitivity ELISA assay (1 g/l). In the same study, significantly higher plasma levels were observed in patients with morphoea when compared with HC and SSc; a similar trend of high values was also observed in patients with primary Raynaud's. The authors reported technical difficulties in TGF activation so total levels of TGF1 were not estimated. Snowden et al. [15] measured active TGF levels in plasma from 39 SSc, nine primary Raynaud's phenomenon patients and 60 HC: active TGF1 was detected in six out of 39 SSc patients only and in none of the other samples. No significant correlation was found between the concentrations of TGF1 and the pattern of cutaneous or visceral involvement, or the levels of N-terminal peptide of type III procollagen (PIIINP). Giacomelli et al. [16] looked for any correlation between the in vitro spontaneous and phytohemagglutinin (PHA)-induced production of TGF1 by peripheral blood mononuclear cells (PBMC) of SSc patients and total serum and plasma levels of TGF1 in the same SSc subject and in HC. No significant difference in total TGF1 levels in plasma, serum or supernatants from unstimulated and stimulated cultures of PBMC was found. Sato et al. [17] measured serum levels of TGF1 in 32 SSc patients and 20 controls using a commercial ELISA kit (R&D); it is unclear whether the authors measured active or total levels of TGF1. TGF1 was found in all samples, with no difference between SSc and HC; no correlation between serum TGF1 and modified Rodnan skin score was found in that study. Finally, Choi et al. [18] , who found increased serum levels of vascular endothelial growth factor (VEGF) in SSc, reported positive correlation of VEGF with serum TGF levels. No numerical TGF concentrations or clinical correlations are described in that paper. In summary, marked variability between the studies is likely to reflect disease heterogeneity, different methodologies employed to study TGF levels and bioactivity and the complex nature of TGF secretion and activation. Differences in study designs, samples, techniques, antibodies and lack of consensus in describing clinical details make any attempt at systematic review or meta-analysis of these data complicated. Finally, although a contemporaneous evaluation of the active TGF1 levels in the affected SSc skin and its serological measurements appears attractive, this approach has some limitations, in particular substantial technical issues concerning the reliable detection of TGF1 ligand in lesional skin and the discrimination between active and latent forms of this growth factor. In fact a number of experiments have been performed with various results [12, 14, 30] .
There are no conclusive data in the literature on any correlation between TGF1 serum concentrations and age in both healthy subjects and various disease groups. Grainger et al. [37] showed no correlation between active TGF and age in either healthy controls or subjects with atherosclerosis, whereas Stefoni et al. [38] reported a weak negative correlation between total TGF1 and age in healthy subjects and in patients on haemodialysis. The latter study did not, however, evaluate active TGF1. In our study we found no correlation between either active or total TGF1 levels and age; our healthy controls were slightly younger than scleroderma patients and yet their serum TGF1 levels were lower than those found in the dcSSc group, which would be in contrast with previous findings [38] . Also, any potential age effect would not negate our findings of lower active TGF1 in dcSSc compared with lcSSc as these groups were very well matched for age.
Difficulties in accurate measurements of active TGF are related to its complex regulation and short half-life in biological fluids (2-3 min). Latent TGF is present in large amounts in platelets, and therefore inaccurate sample handling may lead to the release and activation of latent TGF into plasma from platelets during separation and storage or, in case of serum, during clotting, leading to falsely high concentrations of active TGF1. In fact, significantly higher levels of TGF1 are found in the serum when compared with plasma, which may reflect the release of TGF1 from activated platelets during clot formation [16, and our data] . Therefore, careful and quick sample preparation is mandatory for reliable serological assays of TGF. Finally, antibodies not specific for active 25 kDa TGF1 peptide have been used in older assays, detecting also latent TGF1; at present, highly sensitive and specific immunoassays for active 25kDa TGF1 are being developed.
In summary, detailed assessment and comparison with clinical features may further elucidate the role of circulating pro-fibrotic factors as markers or mediators of disease in SSc. The potential significance of low levels of TGF1 and the relevance of our findings to systemic TGF-trapping strategies in early stage dcSSc justify further study, including prospective longitudinal assessment of circulating levels of active TGF1 in SSc.
